-
"Don't Be Sick" New Book Conference Held in Beijing
Time of Update: 2021-04-22
"Don't Be Sick" New Book Conference Held in Beijing "Don't Be Sick" New Book Launch Conference Held in Beijing "Don't Be Sick" Book Launch Conference Held in Beijing On April 19,
-
China Resources Double Crane: China Resources Secco Finasteride Tablets (1mg) Approved for Listing
Time of Update: 2021-04-19
It is reported that China Resources SECCO has invested RMB 3.
China Resources Secco Finasteride (5mg) is mainly used for the treatment of benign prostatic hyperplasia (BPH) with existing symptoms and passed the consistency evaluation on September 18, 2019.
-
GlaxoSmithKline Benlysta (belyumumab) is recommended and approved by the EU CHMP
Time of Update: 2021-04-19
GlaxoSmithKline (GSK) recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting the approval of Benlysta (Chinese trade name: Beliteng, generic name: belimumab, Belyumumab) intravenous and subcutaneous preparations, combined with background immunosuppressive therapy, are used to treat adult patients with active lupus nephritis (LN).
-
Johnson & Johnson's S1P1 regulator Ponvory (ponesimod) is about to be approved in the EU
Time of Update: 2021-04-19
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (JNJ), recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting approval of Ponvory (ponesimod), which is a once-daily, orally administered drug , Selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease determined by clinical or imaging features.
-
Hengrui Pharmaceuticals ERK Inhibitor Approved for Clinical
Time of Update: 2021-04-19
On March 26, the CDE official website showed that Hengrui's application for clinical trial of extracellular regulatory protein kinase (ERK) inhibitors has been approved by the State Food and Drug Administration by default.
The MAPK signaling pathway is transmitted to multiple targets in the cell via RAS-RAF-MEK-ERK.
-
The national pharmacy renovation begins!
Time of Update: 2021-04-19
Sorting out: XiyuAttention pharmacies that sell medical masks, condoms, and sticky medical devices, the nationwide inspection is coming. 590,000 medical equipment operating companies, the nationwide i
-
The disease control rate exceeds 95%!
Time of Update: 2021-04-19
SourceGuanlan PharmaceuticalOn March 29, Yingli Pharmaceuticals announced that its PI3Kδ inhibitor linperlisib (YY-20394) for the treatment of relapsed/refractory follicular lymphoma phase 2 registration clinical trial was initially completed.
-
The most comprehensive analysis of formula particles: policy, market, competing products, marketing...
Time of Update: 2021-04-19
According to the "Blue Book on the Development of Chinese Medicine Decoction Pieces Industry", the market size of Chinese medicine prescription granules has increased from 2 billion yuan in 2010 to 15 billion yuan in 2018, with a compound growth rate of 28.
-
The results of the fourth batch of national procurement, 4 provinces clarify the landing time
Time of Update: 2021-04-19
Jiangsu On March 19, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fourth Batch of State-Organized Drug Centralized Procurement Results", which officially determined the launch time of the fourth batch of nationally selected results in Jiangsu Province.
-
Sell 16.8 billion to a new high!
Time of Update: 2021-04-19
Table 2: The current situation of obtaining production licenses for Chinese traditional medicines in various regionsSource: company annual report, *is newly added last yearAs the company’s newly established integrated business enterprises actively promote production capacity, the obtained TCM formula granule extraction and preparation production licenses have increased significantly compared with the same period last year.
-
Up to about 1.08 billion yuan, Fuhong Henlius won the right of a BRAF inhibitor from Runxin Biotech
Time of Update: 2021-04-19
Source: Immediate Medicine NewsOn March 29, 2021, Henlius Fuhong announced that it has reached an exclusive license cooperation with Runxin Bio for the BRAF V600E inhibitor RX208.
-
Pfizer announces Phase 3 clinical results of abrocitinib, a new-generation oral JAK1 inhibitor
Time of Update: 2021-04-19
(100mg, 200mg, once a day, orally), positive control drug dupilumab (300mg, baseline 600mg loading dose, once every 2 weeks, subcutaneous injection), placebo efficacy and safety, all patients received topical therapy.
-
Health yuan hits new inhaler medicine again!
Time of Update: 2021-04-19
Figure 1: Healthyuan’s application status of aclidinium bromide inhalation powderSource: CDE official websiteTable 1: The status of key inhalant products declared by Joincare and its subsidiaries earlierSource: Meinenet MED2.
In addition, the clinical application of category 3 imitation of mometasone formoterol inhalation aerosol is under review and approval.
-
Gilead's first TROP-2 target drug Trodelvy enters EU review
Time of Update: 2021-04-19
Gilead recently announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for the targeted anticancer drug Trodelvy (sacituzumab govitecan-hziy, SG), which is used for treatment: previously accepted At least two therapies, at least one of which treats unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) adult patients with locally advanced or metastatic disease.
-
Overview of the U.S. Biosimilar Drug Market 2020
Time of Update: 2021-04-19
S. dollars)In 2020, the overall price of Humira in the US market has increased by about 8% compared to the previous year, and the share of sales in the total global revenue continues to rise to 81.
-
The domestic pharmaceutical packaging material industry, which is constantly catching up and upgrading from bottle cap to bottle body, has a promising future
Time of Update: 2021-04-19
Previously, according to information disclosed by the China Vaccine Industry Association, there are currently more than 60 domestic manufacturers of relevant pharmaceutical packaging materials.
-
Simcere Pharmaceuticals obtains exclusive rights to anti-cancer drug paxalisib in Greater China
Time of Update: 2021-04-19
On March 29, Simcere Pharmaceuticals announced that its subsidiary has signed an exclusive license agreement with Kazia Therapeutics, an Australian oncology drug development company, to introduce the anti-cancer drug paxalisib under investigation in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
-
The Central Commission for Discipline Inspection issued a document to strictly investigate medical corruption, hospital leaders were investigated
Time of Update: 2021-04-19
According to the news of medical network on April 6th, it is the Qingming holiday. The Central Commission for Discipline Inspection issued a document naming medical corruption, hospital leaders were
-
Wanchun Pharmaceutical's new drug Pranabrin submitted a marketing application to the FDA and NMPA
Time of Update: 2021-04-19
A number of studies have shown that Pranabrin can prevent severe CIN caused by multiple chemotherapeutic drugs with different anti-tumor mechanisms.
-
Johnson & Johnson scrapped 15 million doses of new crown vaccine due to confusion and errors in the production process
Time of Update: 2021-04-19
According to overseas media reports on March 31, 15 million doses of Johnson & Johnson vaccine were scrapped due to production errors in the vaccine factory.
